Primary Biliary Cholangitis Therapeutics Market Revenue Outlook: Strategic Insights and Forecast to 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Will the Primary Biliary Cholangitis Therapeutics Market Evolve in Terms of Growth and Size by 2029?
The market size for therapeutics for primary biliary cholangitis has seen a swift expansion in the past few years. There will be an increase from $0.89 billion in 2024 to $1.01 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 13.3%. This significant growth during the historic period is credited to the heightened recognition of autoimmune liver diseases, mounting clinical data supporting growth in liver function testing, intensified investment in hepatology research, and the growing incidence of autoimmune diseases.
The market for primary biliary cholangitis therapeutics is predicted to witness substantial growth in the coming years, expanding to $1.64 billion in 2029 with a CAGR of 12.9%. Reasons for this upward trend during the forecast period include the increased use of second-line treatments, the burgeoning number of new therapeutics in the pipeline, the escalation in combined therapy use, enhanced worldwide access to diagnostics and specialized care, and the proliferation of patient advocacy and educational undertakings. Notable trends projected for the forecast period encompass personalized therapy strategies, the extension of second-line treatments, the attention to non-invasive biomarkers, concentrations on symptom handling, and the incorporation of real-world evidence (RWE).
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25887&type=smp
What factors are expected to fuel Primary Biliary Cholangitis Therapeutics market growth in the coming years?
The surge in liver disease instances is predicted to spur the growth of the primary biliary cholangitis therapeutics market in the future. These diseases encompass a range of conditions that disrupt the liver’s usual activities, often resulting in inflammation, scarring, or even liver failure. The escalation in liver diseases is attributed to an increase in alcohol consumption, which inflicts damage on liver cells and triggers inflammation and chronic liver issues. Therapies for primary biliary cholangitis help to control these diseases by focusing on bile duct inflammation, decelerating the progress of the disease, and conserving the liver’s functionality. The treatments alleviate patient symptoms, improve the quality of their lives, and put off the need for a liver transplant. For example, the Centers for Disease Control and Prevention reported in March 2022, that deaths due to chronic liver diseases in Texas increased to 5,079, up from 4,930 in 2021. Consequently, the escalating occurrence of liver diseases is propelling the expansion of the primary biliary cholangitis therapeutics market.
What Are The Key Findings From The Segmentation Analysis Of The Primary Biliary Cholangitis Therapeutics Market?
The primary biliary cholangitis therapeutics market covered in this report is segmented –
1) By Drug: Ursodeoxycholic Acid, Obeticholic Acid, Other Drugs
2) By Mechanism Of Action (MOA): Receptor Agonist, Receptor Modulator, Enzyme Activator, Enzyme Inhibitor, Other Mechanisms Of Action
3) By Distribution Channel: Hospital Pharmacies, Drug Store And Retail Pharmacies, Online Pharmacies
4) By Use: Human, Veterinary
Subsegments:
1) By Ursodeoxycholic Acid: Branded Ursodeoxycholic Acid, Generic Ursodeoxycholic Acid, Combination Therapies With Ursodeoxycholic Acid
2) By Obeticholic Acid: Monotherapy, Combination Therapy, Branded Obeticholic Acid
3) By Other Drugs: Fibrates, Budesonide, Immunosuppressants, Investigational Drugs Or Pipeline Candidates
How Are Key Trends Driving Expansion In The Primary Biliary Cholangitis Therapeutics Industry?
Leading companies in the primary biliary cholangitis therapeutics marketplace are concentrating on the creation of advanced products and procuring approvals like peroxisome proliferator-activated receptor agonists, in order to enhance bile acid metabolism and decelerate the disease progression. Peroxisome proliferator-activated receptor (PPAR) agonists, are medications which activate PPAR proteins that dictate genes related to metabolism, inflammation and energy balance. For instance, in August 2024, Gilead Sciences Inc., a pharmaceutical establishment based in the US, acquired the accelerated approval from the U.S. Food and Drug Administration (FDA) for their drug, Livdelzi (seladelpar). This drug is meant for the treatment of primary biliary cholangitis (PBC) in adults who have not responded sufficiently to ursodeoxycholic acid (UDCA) or are unable to bear UDCA. Livdelzi is an oral, selective PPARδ agonist that operates by activating the PPARδ receptor to manage genes concerned with reducing liver inflammation, boosting bile acid metabolism, and decelerating the disease progression in primary biliary cholangitis (PBC).
What Are The Most Active Companies In The Primary Biliary Cholangitis Therapeutics Market Today?
Major companies operating in the primary biliary cholangitis therapeutics market are F. Hoffmann-La Roche Ltd, Parvus Therapeutics, Novartis AG, Gilead Sciences Inc., Viatris Inc., Ipsen Pharma, Hanmi Pharmaceutical Co. Ltd., Intercept Pharmaceuticals, Enanta Pharmaceuticals, Mirum Pharmaceuticals, Calliditas Therapeutics AB, Dr. Falk Pharma GmbH, NGM Biopharmaceuticals Inc., Durect Corporation, COUR Pharmaceuticals, HighTide Therapeutics Inc., Pliant Therapeutics Inc., Tiziana Life Sciences, Phenex Pharmaceuticals, Synlogic Therapeutics
Get The Full Report Here:
Which Regional Markets Are Attracting The Most Investment In Primary Biliary Cholangitis Therapeutics?
North America was the largest region in the primary biliary cholangitis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=25887&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
